Skip to main content
Top
Published in: Trials 1/2022

Open Access 01-12-2022 | Coronavirus | Study protocol

High-dose vitamin D substitution in patients with COVID-19: study protocol for a randomized, double-blind, placebo-controlled, multi-center study—VitCov Trial

Authors: Fabienne Jaun, Maria Boesing, Giorgia Lüthi-Corridori, Kristin Abig, Anja Makhdoomi, Nando Bloch, Christina Lins, Andrea Raess, Victoria Grillmayr, Philippe Haas, Philipp Schuetz, Luca Gabutti, Jürgen Muser, Anne B. Leuppi-Taegtmeyer, Stéphanie Giezendanner, Michael Brändle, Jörg D. Leuppi

Published in: Trials | Issue 1/2022

Login to get access

Abstract

Background

The coronavirus disease 19 (COVID-19) pandemic has caused millions of deaths, and new treatments are urgently needed. Factors associated with a worse COVID-19 prognosis include old age (> 65 years), ethnicity, male sex, obesity, and people with comorbidities. Furthermore, vitamin D deficiency was reported as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. According to a recent clinical case series, vitamin D deficiency is a modifiable risk factor, which has the prospect of reducing hospital stay, intensive care, and fatal outcomes. Vitamin D has potent immunomodulatory properties, and its supplementation might improve important outcomes in critically ill and vitamin D-deficient COVID-19 patients. Despite the evidence that supports an association between vitamin D deficiency and COVID-19 severity, there is uncertainty about the direct link. Therefore, the aim of the trial is to assess if high-dose vitamin D supplementation has a therapeutic effect in vitamin D-deficient patients with COVID-19.

Methods

As the trial design, a randomized, placebo-controlled, double-blind, multi-center approach was chosen to compare a high single dose of vitamin D (140,000 IU) followed by treatment as usual (TAU) (VitD + TAU) with treatment as usual only (placebo + TAU) in patients with COVID-19 and vitamin D deficiency.

Discussion

Vitamin D substitution in patients with COVID-19 and vitamin D deficiency should be investigated for efficacy and safety. The study aim is to test the hypothesis that patients with vitamin D deficiency suffering from COVID-19 treated under standardized conditions in hospital will recover faster when additionally treated with high-dose vitamin D supplementation. Latest studies suggest that vitamin D supplementation in patients with COVID-19 is highly recommended to positively influence the course of the disease. With this randomized controlled trial, a contribution to new treatment guidelines shall be made.

Trial registration

ClinicalTrials.​gov NCT04525820 and SNCTP 2020-01401
Literature
1.
go back to reference Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 2020. 382(8):727–33. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 2020. 382(8):727–33.
3.
go back to reference Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13(9):752–61.CrossRef Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13(9):752–61.CrossRef
5.
go back to reference Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirol Carlton Vic. 2018;23(2):130–7.CrossRef Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirol Carlton Vic. 2018;23(2):130–7.CrossRef
6.
go back to reference Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol Baltim Md 1950. 2008;181(10):7090–9. Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol Baltim Md 1950. 2008;181(10):7090–9.
9.
go back to reference Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–25.CrossRef Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–25.CrossRef
10.
go back to reference Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, Madronich S, et al. Epidemic influenza and vitamin D. Epidemiol Infect. 2006;134(6):1129–40.CrossRef Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, Madronich S, et al. Epidemic influenza and vitamin D. Epidemiol Infect. 2006;134(6):1129–40.CrossRef
14.
15.
go back to reference Dancer RCA, Parekh D, Lax S, D’Souza V, Zheng S, Bassford CR, et al. Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). Thorax. 2015;70(7):617–24.CrossRef Dancer RCA, Parekh D, Lax S, D’Souza V, Zheng S, Bassford CR, et al. Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). Thorax. 2015;70(7):617–24.CrossRef
17.
go back to reference Carpagnano GE, Di Lecce V, Quaranta VN, Zito A, Buonamico E, Capozza E, et al. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. J Endocrinol Invest. 2020;9:1–7. Carpagnano GE, Di Lecce V, Quaranta VN, Zito A, Buonamico E, Capozza E, et al. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. J Endocrinol Invest. 2020;9:1–7.
18.
go back to reference Annweiler C, Hanotte B, Grandin de l’Eprevier C, Sabatier J-M, Lafaie L, Célarier T. Vitamin D and survival in COVID-19 patients: a quasi-experimental study. J Steroid Biochem Mol Biol. 2020;204:105771.CrossRef Annweiler C, Hanotte B, Grandin de l’Eprevier C, Sabatier J-M, Lafaie L, Célarier T. Vitamin D and survival in COVID-19 patients: a quasi-experimental study. J Steroid Biochem Mol Biol. 2020;204:105771.CrossRef
19.
go back to reference Annweiler G, Corvaisier M, Gautier J, Dubée V, Legrand E, Sacco G, et al. Vitamin D supplementation associated to better survival in hospitalized frail elderly COVID-19 patients: the GERIA-COVID quasi-experimental study. Nutrients. 2020;12(11):3377. https://doi.org/10.3390/nu12113377.CrossRef Annweiler G, Corvaisier M, Gautier J, Dubée V, Legrand E, Sacco G, et al. Vitamin D supplementation associated to better survival in hospitalized frail elderly COVID-19 patients: the GERIA-COVID quasi-experimental study. Nutrients. 2020;12(11):3377. https://​doi.​org/​10.​3390/​nu12113377.CrossRef
20.
go back to reference Martineau AR, Forouhi NG. Vitamin D for COVID-19: a case to answer? Lancet Diabetes Endocrinol. 2020;8(9):735–6.CrossRef Martineau AR, Forouhi NG. Vitamin D for COVID-19: a case to answer? Lancet Diabetes Endocrinol. 2020;8(9):735–6.CrossRef
22.
go back to reference Park S, Lee MG, Hong S-B, Lim C-M, Koh Y, Huh JW. Effect of vitamin D deficiency in Korean patients with acute respiratory distress syndrome. Korean J Intern Med. 2018;33(6):1129–36.CrossRef Park S, Lee MG, Hong S-B, Lim C-M, Koh Y, Huh JW. Effect of vitamin D deficiency in Korean patients with acute respiratory distress syndrome. Korean J Intern Med. 2018;33(6):1129–36.CrossRef
24.
go back to reference Sabico S, Enani MA, Sheshah E, Aljohani NJ, Aldisi DA, Alotaibi NH, et al. Effects of a 2-week 5000 IU versus 1000 IU vitamin D3 supplementation on recovery of symptoms in patients with mild to moderate Covid-19: a randomized clinical trial. Nutrients. 2021;13(7):2170. https://doi.org/10.3390/nu13072170.CrossRef Sabico S, Enani MA, Sheshah E, Aljohani NJ, Aldisi DA, Alotaibi NH, et al. Effects of a 2-week 5000 IU versus 1000 IU vitamin D3 supplementation on recovery of symptoms in patients with mild to moderate Covid-19: a randomized clinical trial. Nutrients. 2021;13(7):2170. https://​doi.​org/​10.​3390/​nu13072170.CrossRef
25.
go back to reference da Rocha AP, Atallah AN, Aldrighi JM, Pires ALR, Dos Santos Puga ME, Pinto ACPN. Insufficient evidence for vitamin D use in COVID-19: a rapid systematic review. Int J Clin Pract. 2021;75(11):e14649.CrossRef da Rocha AP, Atallah AN, Aldrighi JM, Pires ALR, Dos Santos Puga ME, Pinto ACPN. Insufficient evidence for vitamin D use in COVID-19: a rapid systematic review. Int J Clin Pract. 2021;75(11):e14649.CrossRef
30.
go back to reference Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.CrossRef Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.CrossRef
38.
go back to reference Nussbaumer-Streit B, Mayr V, Ai D, Chapman A, Persad E, Klerings I, et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database Syst Rev [Internet]. 2020;(4) Available from:. https://doi.org/10.1002/14651858.CD013574. Nussbaumer-Streit B, Mayr V, Ai D, Chapman A, Persad E, Klerings I, et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database Syst Rev [Internet]. 2020;(4) Available from:. https://​doi.​org/​10.​1002/​14651858.​CD013574.
39.
go back to reference Lau H, Khosrawipour V, Kocbach P, Mikolajczyk A, Schubert J, Bania J, et al. The positive impact of lockdown in Wuhan on containing the COVID-19 outbreak in China. J Travel Med. 2020;27(3):taaa037.CrossRef Lau H, Khosrawipour V, Kocbach P, Mikolajczyk A, Schubert J, Bania J, et al. The positive impact of lockdown in Wuhan on containing the COVID-19 outbreak in China. J Travel Med. 2020;27(3):taaa037.CrossRef
40.
go back to reference Desai AP, Dirajlal-Fargo S, Durieux JC, Tribout H, Labbato D, McComsey GA. Vitamin K & D deficiencies are independently associated with COVID-19 disease severity. Open Forum Infect Dis. 2021;8(10):ofab408.CrossRef Desai AP, Dirajlal-Fargo S, Durieux JC, Tribout H, Labbato D, McComsey GA. Vitamin K & D deficiencies are independently associated with COVID-19 disease severity. Open Forum Infect Dis. 2021;8(10):ofab408.CrossRef
41.
go back to reference Speakman LL, Michienzi SM, Badowski ME. Vitamins, supplements and COVID-19: a review of currently available evidence. Drugs Context. 2021;10:2021-6–2.CrossRef Speakman LL, Michienzi SM, Badowski ME. Vitamins, supplements and COVID-19: a review of currently available evidence. Drugs Context. 2021;10:2021-6–2.CrossRef
42.
go back to reference di Filippo L, Allora A, Locatelli M, Rovere Querini P, Frara S, Banfi G, et al. Hypocalcemia in COVID-19 is associated with low vitamin D levels and impaired compensatory PTH response. Endocrine. 2021;74(2):219–25.CrossRef di Filippo L, Allora A, Locatelli M, Rovere Querini P, Frara S, Banfi G, et al. Hypocalcemia in COVID-19 is associated with low vitamin D levels and impaired compensatory PTH response. Endocrine. 2021;74(2):219–25.CrossRef
43.
go back to reference Annweiler C, Souberbielle J-C. Vitamin D supplementation and COVID-19: expert consensus and guidelines. Geriatr Psychol Neuropsychiatr Vieil. 2016;1:1. Annweiler C, Souberbielle J-C. Vitamin D supplementation and COVID-19: expert consensus and guidelines. Geriatr Psychol Neuropsychiatr Vieil. 2016;1:1.
Metadata
Title
High-dose vitamin D substitution in patients with COVID-19: study protocol for a randomized, double-blind, placebo-controlled, multi-center study—VitCov Trial
Authors
Fabienne Jaun
Maria Boesing
Giorgia Lüthi-Corridori
Kristin Abig
Anja Makhdoomi
Nando Bloch
Christina Lins
Andrea Raess
Victoria Grillmayr
Philippe Haas
Philipp Schuetz
Luca Gabutti
Jürgen Muser
Anne B. Leuppi-Taegtmeyer
Stéphanie Giezendanner
Michael Brändle
Jörg D. Leuppi
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-022-06016-2

Other articles of this Issue 1/2022

Trials 1/2022 Go to the issue